Profile data is unavailable for this security.
About the company
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
- Revenue in USD (TTM)420.00k
- Net income in USD-22.76m
- Incorporated1996
- Employees12.00
- LocationCyclacel Pharmaceuticals Inc200 Connell Dr Ste 1500BERKELEY HEIGHTS 07922-2811United StatesUSA
- Phone+1 (908) 517-7330
- Fax+1 (866) 271-3466
- Websitehttps://cyclacel.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neubase Therapeutics Inc | 0.00 | -13.73m | 1.57m | 37.00 | -- | 0.1707 | -- | -- | -7.78 | -7.78 | 0.00 | 2.45 | 0.00 | -- | -- | -- | -53.51 | -- | -64.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Link Reservations Inc | 0.00 | -480.90k | 1.59m | 0.00 | -- | -- | -- | -- | -46.51 | -46.51 | 0.00 | -13.99 | 0.00 | -- | -- | -- | -246.84 | -- | -- | -- | -- | -- | -- | -- | -- | -2.43 | -- | -- | -- | -- | -22.69 | -- | -- | -- |
| Mallinckrodt PLC | 1.87bn | -1.67bn | 1.60m | 2.80k | -- | -- | -- | 0.0009 | -177.21 | -177.20 | 94.84 | 58.90 | 0.3829 | 1.53 | 4.77 | 666,392.90 | -34.26 | -12.49 | -39.27 | -15.85 | 20.70 | 35.68 | -89.47 | -44.38 | 1.55 | -0.4599 | 0.603 | -- | -2.53 | -10.31 | -83.00 | -- | -- | -- |
| Stemcell Holdings Inc | 9.98m | 3.10m | 1.64m | -- | -- | -- | 0.5008 | 0.1645 | 0.00008 | 0.00008 | 0.0003 | 0.0002 | 1.12 | -- | 5.20 | -- | 34.90 | -- | 68.19 | -- | 77.19 | -- | 31.04 | -- | -- | -- | 0.00 | -- | 85.10 | -- | 71.82 | -- | -- | -- |
| CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 1.66m | 0.00 | -- | 0.9315 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -19.94m | 1.67m | 4.00 | -- | -- | -- | -- | -64.01 | -64.01 | 0.00 | -0.2389 | 0.00 | -- | -- | 0.00 | -160.06 | -42.39 | -280.99 | -56.41 | -- | -- | -- | -- | -- | -- | 1.14 | -- | -- | -- | 48.52 | -- | -- | -- |
| American Green Inc | -100.00bn | -100.00bn | 1.71m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Aoxing Pharmaceutical Company Inc | 30.11m | -1.46m | 1.74m | 339.00 | -- | 0.0203 | -- | 0.0578 | -0.0192 | -0.0192 | 0.3951 | 0.2507 | 0.496 | 2.32 | 2.56 | -- | -2.41 | -14.54 | -7.06 | -35.45 | 76.19 | 68.51 | -4.85 | -37.69 | 0.7368 | 0.3387 | 0.6052 | -- | 26.88 | 37.20 | -62.49 | -- | -38.80 | -- |
| Procyon Corp | 4.70m | -314.48k | 1.77m | 17.00 | -- | 0.7961 | -- | 0.3769 | -0.0388 | -0.0388 | 0.5804 | 0.2901 | 1.40 | 1.95 | 8.58 | 276,481.20 | -8.90 | 3.52 | -10.60 | 4.23 | 77.60 | 73.30 | -6.35 | 2.52 | 2.70 | -- | 0.00 | -- | -3.22 | 3.11 | 70.44 | -- | 30.98 | -- |
| Cyclacel Pharmaceuticals Inc | 420.00k | -22.76m | 1.79m | 12.00 | -- | 2.37 | -- | 4.27 | -26.72 | -26.72 | 0.4924 | 0.5732 | 0.0228 | -- | 0.1106 | -- | -122.40 | -57.58 | -212.95 | -69.81 | -- | -- | -5,370.24 | -18,789.29 | -- | -170.83 | 0.00 | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
| Qualigen Therapeutics Inc | 0.00 | -12.48m | 1.86m | 4.00 | -- | -- | -- | -- | -2.46 | -2.64 | 0.00 | -0.3923 | 0.00 | -- | -- | 0.00 | -118.15 | -- | -364.72 | -- | 21.30 | -- | -- | -- | -- | -7.41 | -- | -- | -- | -- | 10.22 | -- | -- | -- |
| Ensysce Biosciences Inc | 2.23m | -10.63m | 1.87m | 7.00 | -- | -- | -- | 0.8364 | -5.28 | -5.28 | 0.9876 | -0.1026 | 0.5191 | -- | 11.92 | 318,645.70 | -247.32 | -17.68 | -- | -19.42 | -- | -- | -476.40 | -715.78 | -- | -30.28 | 4.20 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
| Limitless X Holdings Inc | 20.06m | -16.12m | 1.99m | 12.00 | -- | -- | -- | 0.0992 | -4.06 | -4.06 | 5.06 | -3.24 | 3.30 | 2.31 | 39.61 | 1,671,340.00 | -265.35 | -- | -- | -- | 77.66 | -- | -80.37 | -- | 0.0186 | -15.77 | -- | -- | -65.83 | -- | -60.80 | -- | -- | -- |
| SOHM Inc | -100.00bn | -100.00bn | 2.00m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Data as of Apr 30 2024. Currency figures normalised to Cyclacel Pharmaceuticals Inc's reporting currency: US Dollar USD
7.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Altium Capital Management LPas of 31 Dec 2023 | 37.98k | 2.88% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 24.22k | 1.84% |
| Point72 Asset Management LPas of 31 Dec 2023 | 15.33k | 1.16% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 14.44k | 1.10% |
| McIlrath & Eck LLCas of 31 Dec 2023 | 832.00 | 0.06% |
| Tower Research Capital LLCas of 31 Dec 2023 | 807.00 | 0.06% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Dec 2023 | 126.00 | 0.01% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 80.00 | 0.01% |
| Wells Fargo Clearing Services LLCas of 31 Dec 2023 | 33.00 | 0.00% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 25.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
